News summary

Senescence field heads to Stanford to settle what counts as proof

Source: Longevity Technology • Published: 20 Nov 2026, 17:39

Summarized by Masters of Longevity from Longevity Technology.

A summit sought consensus on biomarkers and proof standards for senotherapeutics.

Senescence field heads to Stanford to settle what counts as proof
Key Takeaways
  • Researchers convened to set shared senotherapeutic biomarker definitions.
  • Consensus is needed to detect human senescent cells reliably.
  • Standardization has not established that targeting senescence treats disease.
Read the full article at Longevity Technology ↗

Continue exploring

Recommended MoL Picks

MoL PickReducing Inflammation from Ageing Cells: What a Mouse Study FoundResearchers reduced the inflammatory signals released by cells that had stopped dividing. Older mice also improved on some strength and frailty tests. Whether this approach could help people remains unknown.MoL PickCan You Really Measure Whether You’re Aging More Slowly?A younger epigenetic-age score can look like proof that an intervention is working. A major new analysis shows which clocks detect change—and why movement is not yet the same as longer healthspan.MoL PickApoB: The cholesterol signal LDL can missIn longevity medicine, the useful biomarkers are not always the exotic ones. ApoB is a relatively simple blood test that can sharpen cardiovascular prevention when LDL-C looks reassuring but particle burden remains high.